相关实验视频

Updated: May 11, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

基于模型的分析,对皮奥格利塔与代谢功能障碍相关的脂肪肝炎患者的组织学结果之间的关系进行了分析

Quyen Thi Tran^1,2, Tham Thi Bui^3,4, Lien Thi Ngo^1,2

¹Faculty of Pharmacy, Phenikaa University, Hanoi, Vietnam.

CPT: pharmacometrics & systems pharmacology

|April 18, 2025

概括

皮奥格利塔有效地改善了代谢功能障碍相关的脂肪肝炎 (MASH) 患者的肝脏组织学和酶. 这一元分析提供了评估新MASH治疗的模型.

科学领域:

肝病学肝病学是一种肝病学.
药理学药理学是指药理学的学科.
数据科学数据科学数据科学

背景情况:

代谢功能障碍相关的脂肪肝炎 (MASH) 影响着大量人群,批准的治疗方法有限.
皮奥格利塔是一种2型糖尿病药物,用于MASH的非标签.
需要对现有的MASH疗法进行定量疗效评估.

研究的目的:

用基于模型的元分析量化评估pioglitazone在改善MASH组织学参数和肝酶方面的有效性.
开发对pioglitazone对MASH的影响的预测模型.
为评估新型MASH治疗方法建立一个基准.

主要方法:

在PubMed和ClinicalTrials.gov.gov上进行了系统的文献搜索.
进行了基于模型的元分析,为组织学结果生成虚拟数据,并应用后勤,韦布尔和指数模型来匹配数据.
模型性能使用视觉预测检查,引导方法和堆叠条形图进行评估.

主要成果:

分析了8项涉及540名患者的研究.
皮奥格利塔显著改善了肥胖症,炎症,气球膨胀和纤维化.
疗效证明了和气球的剂量和时间依赖关系,以及炎症和纤维化的线性关系. 韦布尔模型有效地描述了ALT和AST的变化.

结论:

皮奥格利塔在MASH患者中显示出显著的组织学和生化改善.
开发的定量模型为评估皮奥格利塔的有效性提供了一个框架.
这些模型可以作为评估新的MASH向疗法的基准.

关键词:

马什 (MASH) 是一个非常重要的产品.我们的MBMA是MBMA.组织学组织学肝脏酶肝脏酶肝脏酶皮奥格利塔 (pioglitazone) 是一种药物.

更多相关视频

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Feedback Loops

Feedback Loops

In most cases, excessive hormone production is prevented by negative feedback—a loop that starts with a stimulus inducing the release of a particular substance, like a hormone, to maintain a certain level before triggering a signal that results in a decrease in further release of the hormone.

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...